regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-06. Numbers and descriptions here follow the published literature rather than marketing material.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
Legal status varies by country. In some places, cardarine is controlled under medicines or psychoactive substances laws; in others, it may be sold with minimal oversight as a research chemical. Customs agencies have intercepted shipments, and several national health agencies have issued warnings about products marketed for bodybuilding or performance enhancement. The lack of a standardized pharmaceutical supply means identity, purity, and contamination levels can differ widely between samples. These factors make cardarine a regulatory and public health concern rather than a conventional prescription drug.
Cardarine is a common name for GW501516, a synthetic compound first described in the 1990s as a selective agonist of the peroxisome proliferator-activated receptor delta. It was studied in preclinical models for metabolic and cardiovascular conditions, but it has not been approved as a medicine in the United States, Europe, or other major jurisdictions. Retail products labeled as cardarine are generally research chemicals or supplements, not pharmaceutical formulations. Because human safety and efficacy data remain limited, regulatory agencies treat it as an unapproved substance rather than a therapeutic product.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
This distinction is particularly relevant in structural biology, materials science, and computational chemistry, where hydrogen bonding spans a continuum from weak van der Waals-like interactions to nearly covalent bonding. Hydrogen bonding can occur between separate molecules (intermolecular) or within different parts of the same molecule (intramolecular). Its strength varies considerably, depending on geometry, environment, and the donor-acceptor pair, typically ranging from 4.2 to 167.4 kJ/mol (1 to 40 kcal/mol). This places hydrogen bonds stronger than van der Waals interactions but generally weaker than covalent or ionic bonds. Hydrogen bonding plays a fundamental role in chemistry, biology, and materials science. It is responsible for the anomalously high boiling point of water, the stabilization of protein and nucleic acid structures, and key properties of materials like paper, wool, and hydrogels. In biological systems, hydrogen bonds mediate molecular recognition, enzyme catalysis, and DNA replication, while in materials science, they contribute to self-assembly, adhesion, and supramolecular organization.
== Disruptions and disorders == Regional delta wave activity not associated with NREM sleep was first described by W. Grey Walter, who studied cerebral hemisphere tumors. Disruptions in delta wave activity and slow wave sleep are seen in a wide array of disorders. In some cases there may be increases or decreases in delta wave activity, while others may manifest as disruptions in delta wave activity, such as alpha waves presenting in the EEG spectrum. Delta wave disruptions may present as a result of physiological damage, changes in nutrient metabolism, chemical alteration, or may also be idiopathic. Disruptions in delta activity is seen in adults during states of intoxication or delirium and in those diagnosed with various neurological disorders such as dementia or schizophrenia.
== Principles == Proximity labeling relies on a labeling enzyme that can biotinylate nearby biomolecules promiscuously. Biotin labeling can be achieved through several different methods, depending on the species of labeling enzyme. BioID and TurboID rely on exogenous biotin supplementation; APEX and APEX2 utilize exogenous biotin phenol and hydrogen peroxide.
== Description == Like all holometabolic insects, T. molitor goes through four life stages: egg, larva, pupa, and adult. Larvae typically measure about 2.5 centimetres (0.98 in) or more. Adults are generally 1.25 to 1.8 centimetres (0.49 to 0.71 in) in length. T. molitor is dark brown or black as an adult, with larvae up to 1.25 inches (3.2 cm) long and adults up to 0.75 inches (1.9 cm) long. The yellow mealworm beetle can be differentiated from other beetles, due to the linear grooves that are evenly divided and run along the abdomen. The beetle has only four tarsal segments on its hind legs. Most ground beetles, which are similar in size to Tenebrio molitor, have five tarsal segments. Commonly mistaken with the black mealworm beetle (T. obscurus), key variations in regard to size and shape distinguish these two. The abdomen of the adult black mealworm beetle is more rounded and ends in a pointed tip, as opposed to the more rectangular and blunt-ended abdomen of the yellow mealworm beetle. The larvae of T. molitor are lighter colored than those of T. obscurus.
Sources: en.wikipedia.org
Oskar Stross, Austrian Consul General Mervyn Whitfield, Political Branch, Public Security, Alexandria, 1917 General Sir Reginald Wingate, 1915 Judge Youssef Zulficar Pasha (Grand Cordon) Oswald Longstaff Prowde, English civil engineer Lt Colonel William John Ainsworth, CBE DSO Durham Light Infantry (3rd Class 1919),
Winged alates mate through nuptial flights in June, but wingless queens and males have a different way of reproduction. During the fall, the wingless queens mate inside the nest. Then, the colony splits and the queen departs with a portion of the colony's workers, in order to start a new colony. The queen must leave the nest, as the workers will try to kill her if she does not. The wingless males mate with the queens while they are still in cocoons, and, unlike Cardiocondyla, do not fight. The males mate with the queens for up to 40 hours, and it is thought that they guard the queens in order to prevent other males from mating with them.
Paralytic peptides are a family of short (23 amino acids) insect peptides that halt metamorphosis of insects from larvae to pupae. These peptides contain one disulphide bridge. The family includes growth-blocking peptide (GBP) of Mythimna separata (Oriental armyworm) and the paralytic peptides from Manduca sexta (tobacco hawkmoth), Heliothis virescens (noctuid moth), and Spodoptera exigua (beet armyworm) as well as plasmatocyte-spreading peptide (PSP1).
=== Production === Aqueous humour is secreted into the posterior chamber by the ciliary body, specifically the non-pigmented epithelium of the ciliary body (pars plicata). 5 alpha-dihydrocortisol, an enzyme inhibited by 5-alpha reductase inhibitors, may be involved in production of aqueous humour.
The α-globin chains are encoded by two closely linked genes HBA1 and HBA2 on chromosome 16; in a person with two copies on each chromosome, a total of four loci encode the α chain. Two alleles are maternal and two alleles are paternal in origin. Alpha-thalassemias result in decreased alpha-globin production, resulting in an excess of β chains in adults and excess γ chains in fetus and newborns.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
No. Cardarine has not received approval for human therapeutic use in major jurisdictions. It remains an investigational compound.